Anil Koul

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10704776/publications.pdf

Version: 2024-02-01

36 papers	5,487 citations	186265 28 h-index	361022 35 g-index
37 all docs	37 docs citations	37 times ranked	5859 citing authors

#	Article	IF	Citations
1	The challenge of new drug discovery for tuberculosis. Nature, 2011, 469, 483-490.	27.8	887
2	Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages. Science, 2004, 304, 1800-1804.	12.6	494
3	Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chemical Biology, 2007, 3, 323-324.	8.0	475
4	Interplay between mycobacteria and host signalling pathways. Nature Reviews Microbiology, 2004, 2, 189-202.	28.6	321
5	Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline. PLoS ONE, 2014, 9, e102135.	2.5	320
6	Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis. Journal of Biological Chemistry, 2008, 283, 25273-25280.	3.4	297
7	Structure of the mycobacterial ATP synthase F _o rotor ring in complex with the anti-TB drug bedaquiline. Science Advances, 2015, 1, e1500106.	10.3	224
8	Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nature Communications, 2014, 5, 3369.	12.8	219
9	Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue. Antimicrobial Agents and Chemotherapy, 2009, 53, 1290-1292.	3.2	203
10	Disruption of <i>mptpB</i> impairs the ability of <i>Mycobacterium tuberculosis</i> to survive in guinea pigs. Molecular Microbiology, 2003, 50, 751-762.	2.5	174
11	Cloning and Characterization of Secretory Tyrosine Phosphatases of <i>Mycobacterium tuberculosis</i>. Journal of Bacteriology, 2000, 182, 5425-5432.	2.2	170
12	Bactericidal mode of action of bedaquiline. Journal of Antimicrobial Chemotherapy, 2015, 70, 2028-2037.	3.0	161
13	Targeting Energy Metabolism in <i>Mycobacterium tuberculosis</i> , a New Paradigm in Antimycobacterial Drug Discovery. MBio, 2017, 8, .	4.1	157
14	Essentiality of FASII pathway for Staphylococcus aureus. Nature, 2010, 463, E3-E3.	27.8	142
15	Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nature Chemical Biology, 2016, 12, 87-93.	8.0	121
16	A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins: Structure, Function and Bioinformatics, 2007, 67, 971-980.	2.6	113
17	Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase. PLoS ONE, 2011, 6, e23575.	2.5	110
18	The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress. Scientific Reports, 2015, 5, 10333.	3.3	101

#	Article	IF	Citations
19	Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localization. Microbiology (United Kingdom), 2001, 147, 2307-2314.	1.8	95
20	Transcriptional Control of the Mycobacterial<i>embCAB</i>Operon by PknH through a Regulatory Protein, EmbR, In Vivo. Journal of Bacteriology, 2006, 188, 2936-2944.	2.2	92
21	Novel Antibiotics Targeting Respiratory ATP Synthesis in Gram-Positive Pathogenic Bacteria. Antimicrobial Agents and Chemotherapy, 2012, 56, 4131-4139.	3.2	79
22	Respiratory ATP synthesis: the new generation of mycobacterial drug targets?. FEMS Microbiology Letters, 2010, 308, 1-7.	1.8	72
23	Cytotoxic activity of nucleoside diphosphate kinase secreted from Mycobacterium tuberculosis. FEBS Journal, 2003, 270, 625-634.	0.2	68
24	Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nature Communications, 2017, 8, 167.	12.8	58
25	Phosphoprotein phosphatase of Mycobacterium tuberculosis dephosphorylates serineâ€“threonine kinases PknA and PknB. Biochemical and Biophysical Research Communications, 2003, 311, 112-120.	2.1	57
26	Role of Protein Kinase G in Growth and Glutamine Metabolism of Mycobacterium bovis BCG. Journal of Bacteriology, 2005, 187, 5852-5856.	2.2	57
27	Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. Journal of Infectious Diseases, 2018, 218, 748-756.	4.0	57
28	Nucleoside diphosphate kinase ofMycobacterium tuberculosisacts as GTPase-activating protein for Rho-GTPases. FEBS Letters, 2004, 571, 212-216.	2.8	31
29	Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model. PLoS ONE, 2015, 10, e0126959.	2.5	30
30	Advances and strategies in discovery of new antibacterials for combating metabolically resting bacteria. Drug Discovery Today, 2013, 18, 250-255.	6.4	24
31	Pharmacokinetics-Pharmacodynamics of a Respiratory Syncytial Virus Fusion Inhibitor in the Cotton Rat Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 4534-4539.	3.2	23
32	The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatis. Journal of Antibiotics, 2014, 67, 835-837.	2.0	18
33	Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1<i>H</i>-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus. Journal of Medicinal Chemistry, 2020, 63, 8046-8058.	6.4	16
34	Respiratory syncytial virus: a prioritized or neglected target?. Future Medicinal Chemistry, 2010, 2, 1523-1527.	2.3	13
35	Synthesis, characterization and biological activity of fluorescently labeled bedaquiline analogues. RSC Advances, 2016, 6, 108708-108716.	3.6	8
36	Mycobacterial ATP synthase as drug target. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 27.	1.0	0